Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years

References

• Cheson B D, Bennett J M, Grever M, Kay N, Keating M J, O'Brien S, et al. National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Dighiero G, Hamblin T J. Chronic lymphocytic leukaemia. Lancet 2008; 371: 1017–1029
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson B D, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008
   Web of Science ®Google Scholar
• Rai K R, Peterson B, Appelbaum F R, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757
   PubMed Web of Science ®Google Scholar
• Keating M J, Flinn I, Jain V, Binet J-L, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070–4078
   PubMed Web of Science ®Google Scholar
• Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007; 21: 12–17
   PubMed Web of Science ®Google Scholar
• Paneesha S, Milligan D W. Stem cell transplantation for chronic lymphocytic leukemia. Br J Haematol 2004; 128: 145–152
   Web of Science ®Google Scholar
• Michallet M, Archimbaud E, Bandini G, Rowlings P A, Deeg H J, Gahrton G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic-lymphocytic leukemia. Ann Internal Med 1996; 124: 311–315
   PubMed Web of Science ®Google Scholar
• Khouri I F, Przepiorka D, van Besian K, O'Brien S, Palmer J L, Lerner S, et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 1997; 97: 466–473
   PubMed Web of Science ®Google Scholar
• Mattsson J, Uzunel M, Remberger M, Ljungman P, Kimby E, Ringden O, et al. Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia 2000; 14: 247–254
   PubMed Web of Science ®Google Scholar
• Doney K C, Chauncey T, Appelbaum F R. Seattle Bone Marrow Transplant Team. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant 2002; 29: 817–823
   PubMed Web of Science ®Google Scholar
• Pavletic Z S, Arrowsmith E R, Bierman P J, Goodman S A, Vose J M, Tarantolo S R, et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 2002; 25: 717–722
   Web of Science ®Google Scholar
• Sorror M L, Maris M B, Sandmaier B M, Storer B E, Stuart M J, Hegenbart U, et al. Hematopoietic cell transplantation conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2002; 23: 3819–3829
   Web of Science ®Google Scholar
• Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747–2753
   PubMedGoogle Scholar
• Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003; 17: 841–848
   PubMed Web of Science ®Google Scholar
• Dreger P, Ritgen M, Bottcher S, Schmitz N, Kneba M. The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile?. Leukemia 2005; 19: 1135–1138
   PubMed Web of Science ®Google Scholar
• Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3433–3438
   PubMed Web of Science ®Google Scholar
• Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F. How we treat refractory CLL. Blood 2006; 107: 1276–1283
   PubMed Web of Science ®Google Scholar
• Toze C L, Galal A, Barnett M J, Shepherd J D, Conneally E A, Hogge D E, et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant 2005; 36: 825–830
   PubMed Web of Science ®Google Scholar
• Giné E, Moreno C, Esteve J, Montserrat E. The role of stem-cell transplantation in chronic lymphocytic leukemia risk-adapted therapy. Best Pract Res Clin Haematol 2007; 20: 529–543
   PubMed Web of Science ®Google Scholar
• Khouri I F, Keating M J, Saliba R M, Champlin R E. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 2002; 4: 217–221
   PubMed Web of Science ®Google Scholar
• Khouri I F, Saliba R M, Admirand J, O'Brien S, Lee M-S, Korbling M, et al. Graft-versus-leukaemia effect after nonmyeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007; 137: 355–363
   PubMed Web of Science ®Google Scholar
• Dreger P, Stilgenbauer S, Benner A, Ritgen M, Krober A, Kneba M, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 2004; 103: 2850–2858
   PubMed Web of Science ®Google Scholar
• Ritgen M, Lange A, Stilgenbauer S, Dohner H, Bretscher C, Bosse H, et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2003; 101: 2049–2053
   PubMed Web of Science ®Google Scholar
• Gribben J G, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea E P, Fisher D C, et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood 2005; 106: 4389–4396
   PubMed Web of Science ®Google Scholar
• Banerji V, Johnston J B, Sefte M D. The role of hematopoietic stem cell transplantation in Chronic Lymphocytic Leukemia. Transfus Apher Sci 2007; 37: 57–62
   PubMed Web of Science ®Google Scholar
• Pavletic S Z, Khouri I F, Haagenson M, King R J, Bierman P J, Bishop M R, et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: Results from the centre for International Blood and Marrow Transplant Research. J Clin Oncol 2005; 23: 5788–5794
   PubMed Web of Science ®Google Scholar